Rocket Pharmaceuticals, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020; filed March 1, 2021. The filing also reports unaudited fourth-quarter results. Unless stated otherwise, financial amounts below are in U.S. dollars.
Business context
Rocket is a clinical-stage biotechnology company developing gene therapies for rare diseases. Its pipeline includes four ex vivo lentiviral-vector programs—Fanconi anemia (FA), leukocyte adhesion deficiency-I (LAD-I), pyruvate kinase deficiency (PKD) and infantile malignant osteopetrosis (IMO)—and an in vivo AAV program for Danon disease. The company has no approved products and has not generated product revenue.
Financial performance and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $106.4 million | $58.6 million |
| General and administrative expense | $27.9 million | $17.5 million |
| Total operating expenses / operating loss | $134.3 million | $76.2 million |
| Net loss | $139.7 million | $77.3 million |
| Basic and diluted loss per share | $2.52 | $1.58 |
| Cash, cash equivalents and investments at year-end | $482.7 million | $304.1 million |
| Total assets / total liabilities | $590.8 million / $87.3 million | $372.1 million / $64.8 million |
FY2020 cash used in operating activities was $74.6 million, versus $64.7 million in 2019; investing activities used $96.6 million and financing activities provided $283.0 million. The filing reports no revenue-based margins; margins are not meaningful for this pre-revenue business. Current assets were $487.3 million against current liabilities of $32.6 million.
At December 31, 2020, convertible-note principal was $5.15 million due in 2021 and $38.35 million due in 2022; carrying values were $4.9 million and $35.1 million, respectively. The company also reported $20.6 million of finance-lease liabilities, primarily associated with its Cranbury facility. Total disclosed contractual commitments were $100.3 million, including lease obligations and notes.
Material changes and unusual items
- Net loss widened by $62.4 million year over year. R&D expense rose $47.8 million and G&A rose $10.4 million. R&D growth included $26.5 million of non-cash expense associated with a warrant issued to a related party, as well as higher manufacturing, personnel and clinical-trial costs.
- In December 2020, Rocket raised approximately $280.8 million net from a public offering of 5.34 million shares at $56 per share. Separately, $8.5 million principal amount of 2022 notes converted into 298,562 shares.
- FY2020 fourth-quarter revenue was $0; operating expenses were $59.2 million, operating loss was $59.2 million and net loss was $60.9 million, or $1.09 per share. Fourth-quarter 2019 net loss was $19.9 million, or $0.39 per share. The filing does not provide a clear quarterly breakdown of expense categories.
- Management estimated existing cash, cash equivalents and investments would fund operating expenses and capital expenditures into the second half of 2023. This is an estimate, not a guarantee, and depends on development costs and other factors.
Pipeline, outlook and key risks
- Danon disease (RP-A501): Five patients had been treated in the Phase 1 trial by year-end. Low-dose patients showed cardiac LAMP2B expression and preliminary biomarker findings, but one of two higher-dose patients experienced a serious immune-related event involving reversible thrombocytopenia and acute kidney injury. Updated data were expected in the second half of 2021.
- FA (RP-L102): Interim results from seven patients showed preliminary engraftment in five; two patients with at least 12 months’ follow-up had increasing engraftment and stable blood counts. One patient developed progressive bone-marrow failure after influenza and subsequently received a transplant. Longer-term data were expected in the second quarter of 2021.
- LAD-I (RP-L201): Three pediatric patients had been treated in reported interim data, with hematopoietic reconstitution and early CD18-expression results. No drug-related serious or severe adverse events were reported through the stated cutoff. Initial Phase 2 data were expected in the second quarter of 2021.
- PKD (RP-L301): One treated patient had hemoglobin rise from approximately 7.4 to 14.3 g/dL at three months and had not required further transfusions by the data cutoff. A second patient had recently been treated. Updated data were expected in the second half of 2021.
- IMO (RP-L401): The Phase 1 trial began in the fourth quarter of 2020, with recruitment ongoing; initial data were expected in the second half of 2021.
- Management expected R&D spending to rise as programs advanced and anticipated up to $9.5 million of non-recurring facility buildout expense in 2021. The Cranbury facility was preparing for GMP manufacturing, targeted to begin in 2021; Rocket had no prior company-level manufacturing experience and continued to rely on third parties.
- Key risks include clinical efficacy and safety uncertainty, small patient populations and enrollment delays, COVID-19 disruption, manufacturing and supply constraints, regulatory approval and reimbursement uncertainty, reliance on licensed intellectual property, and the need for future capital. The company stated that it might need to refinance or repay notes at maturity; additional equity financing could dilute shareholders.
- The filing reports an unqualified audit opinion and effective internal control over financial reporting as of year-end. The auditor identified R&D expense accruals—approximately $15 million at year-end—as a critical audit matter because estimating vendor services and costs requires judgment.
Important facts for investors to verify
- Subsequent clinical updates, including durability, patient follow-up, safety events and whether preliminary findings are confirmed in larger or longer-term datasets.
- Actual timing, cost and regulatory readiness of the Cranbury manufacturing facility, and the company’s ability to scale reliable clinical and future commercial supply.
- Cash burn and runway against management’s second-half 2023 estimate, including any changes in trial scope, facility spending or financing needs.
- Convertible-note repayment, conversion or refinancing outcomes, and potential dilution from outstanding options, warrants and future equity issuance.
- The related-party warrant terms and any additional warrants tied to asset identification, alongside the associated expense and potential dilution.
- Whether trial progress, regulatory requirements, reimbursement prospects and intellectual-property rights support eventual commercialization; no product approval or product-sales revenue had been achieved as of the filing.